BPCA incentives include which primary outcome?

BPCA incentives include which primary outcome?

• A. Patent extension for pediatric studies
• B. Extra time for post-market surveillance
• C. Regulatory fee waivers
• D. Tax credits for new pediatric indications

Answer: (A)

The incentive at the heart of BPCA is to reward sponsors who conduct pediatric studies with an extension of market protection. Specifically, completing approved pediatric studies and updating labeling earns six months of pediatric exclusivity, which adds to the term of any existing patent or market protection. This creates a tangible benefit for bringing pediatric data into the labeling, delaying generic competition and effectively extending the product’s protection in children. Other options aren’t the main payoff of BPCA. It isn’t about extra time for post-market surveillance, nor does it provide regulatory fee waivers or tax credits for new pediatric indications. The key reward is that six-month exclusivity period that promotes pediatric research and better, safer use in children.

The incentive at the heart of BPCA is to reward sponsors who conduct pediatric studies with an extension of market protection. Specifically, completing approved pediatric studies and updating labeling earns six months of pediatric exclusivity, which adds to the term of any existing patent or market protection. This creates a tangible benefit for bringing pediatric data into the labeling, delaying generic competition and effectively extending the product’s protection in children.

Other options aren’t the main payoff of BPCA. It isn’t about extra time for post-market surveillance, nor does it provide regulatory fee waivers or tax credits for new pediatric indications. The key reward is that six-month exclusivity period that promotes pediatric research and better, safer use in children.